Acesso livre
Acesso livre

Infectologia

Dois imunologistas explicam quanto tempo dura a imunidade protetora contra COVID-19 após infecção ou vacinação.

8 Mar, 2022 | 18:34h

How long does protective immunity against COVID-19 last after infection or vaccination? Two immunologists explain – The Conversation

A próxima variante: 3 questões centrais sobre o que vem depois da Ômicron.

8 Mar, 2022 | 18:33h

The next variant: three key questions about what’s after Omicron – Nature

[Comunicado de imprensa – ainda não publicado] Nova vacina da Sanofi e GSK demonstra forte proteção contra Covid-19 grave.

8 Mar, 2022 | 18:32h

Comentário: New vaccine demonstrates strong protection against severe Covid-19 in clinical trials – CNN

Comunicado de imprensa: Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine

Revisão sistemática | Anticoagulantes para pessoas internadas com COVID-19.

8 Mar, 2022 | 17:53h

Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library

Resumo: Do blood thinners prevent people who are hospitalised with COVID-19 from developing blood clots? – Cochrane Library

Conteúdo relacionado: Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.

COVID-19: como a Ômicron ultrapassou a Delta, em 3 gráficos.

8 Mar, 2022 | 17:51h

COVID-19: How Omicron overtook Delta in three charts – Nature

Artigos de revisão | Manifestações cutâneas da infecção pelo SARS-CoV-2.

8 Mar, 2022 | 17:43h

Cutaneous Manifestations of SARS-CoV-2 Infection – American Journal of Clinical Dermatology

Common skin signs of COVID-19 in adults: An update – Cleveland Clinic Journal of Medicine

Série Lancet | Envelhecimento com HIV.

8 Mar, 2022 | 17:38h

Página principal: Ageing with HIV

Editoriais:

Ageing with HIV

Time to tackle late diagnosis

Séries:

Delayed presentation of HIV among older individuals: a growing problem

How health systems can adapt to a population ageing with HIV and comorbid disease

Biological ageing with HIV infection: evaluating the geroscience hypothesis

Intersectionality of stigmas and health-related quality of life in people ageing with HIV in China, Europe, and Latin America

Estudo randomizado | Eficácia e segurança de mudar para um regime com 2 medicamentos (dolutegravir/lamivudina) vs. continuar com um regime de 3 a 4 medicamentos visando à manutenção da supressão virológica em adultos portadores de HIV-1.

8 Mar, 2022 | 17:36h

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With HIV-1: Week 48 Results From the Phase 3, Non-inferiority SALSA Randomized Trial – Clinical Infectious Diseases

Recomendações WSES/GAIS/WSIS/SIS-E/AAST para pacientes com infecções cutâneas e de partes moles.

8 Mar, 2022 | 17:17h

WSES/GAIS/WSIS/SIS-E/AAST global clinical pathways for patients with skin and soft tissue infections – World Journal of Emergency Surgery

[Preprint] Estudo RECOVERY mostra que baricitinibe reduz mortes em pacientes internados com COVID-19.

8 Mar, 2022 | 16:22h

Comunicado de imprensa: RECOVERY trial shows Baricitinib reduces deaths in patients hospitalised with COVID-19 – University of Oxford

Estudo original: Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis – medRxiv

Comentários:

Arthritis drug reduces mortality in severe COVID-19, huge clinical trial finds – Science

Covid-19: Anti-inflammatory treatment baricitinib reduces deaths in patients admitted to hospital, finds trial – The BMJ

Another life-saving Covid drug identified – BBC

Conteúdos relacionados:

WHO recommends two new drugs (Baricitinib and Sotrovimab) to treat COVID-19.

RCT: Baricitinib reduced mortality in hospitalized adults with COVID-19.

Randomized trial: Baricitinib plus remdesivir reduce recovery time in patients with COVID-19

 

Comentário do autor no Twitter (fio – clique para saber mais)

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.